[1]
Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Büller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Archives of internal medicine. 1999 Feb 22:159(4):337-45
[PubMed PMID: 10030306]
Level 1 (high-level) evidence
[2]
Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984 Nov-Dec:4(6):297-307
[PubMed PMID: 6393073]
[3]
Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DE Jr. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American journal of medicine. 2000 Nov:109(7):523-30
[PubMed PMID: 11063952]
[4]
Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. The Cochrane database of systematic reviews. 2012 Dec 12:12(12):CD001733. doi: 10.1002/14651858.CD001733.pub3. Epub 2012 Dec 12
[PubMed PMID: 23235582]
Level 1 (high-level) evidence
[5]
Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Alimentary pharmacology & therapeutics. 2013 May:37(9):845-54. doi: 10.1111/apt.12279. Epub 2013 Mar 13
[PubMed PMID: 23489011]
Level 1 (high-level) evidence
[6]
Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul:34(1):50-97
[PubMed PMID: 3308412]
[7]
Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Experimental and clinical cardiology. 2004 Summer:9(2):103-11
[PubMed PMID: 19641695]
[8]
Kamphuis J, Smits P, Thien T. Vascular effects of pentoxifylline in humans. Journal of cardiovascular pharmacology. 1994 Oct:24(4):648-54
[PubMed PMID: 7528848]
[9]
Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R, Lupattelli G, Santambrogio L, Mannarino E. Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. European journal of clinical pharmacology. 1991:41(6):511-5
[PubMed PMID: 1667754]
Level 1 (high-level) evidence
[10]
Brasileiro JL, Inoye CM, Aydos RD, Silva IS, Falcão GR, Marks G, Pereira DM. Ischemia and reperfusion of rat small intestine using pentoxyfilline and prostaglandin E1. Acta cirurgica brasileira. 2013 Nov:28(11):767-73
[PubMed PMID: 24316743]
[11]
Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. European review for medical and pharmacological sciences. 2011 Sep:15(9):1003-9
[PubMed PMID: 22013722]
[12]
Kwiecień S, Brzozowski T, Konturek PC, Pawlik MW, Pawlik WW, Kwiecień N, Konturek SJ. Gastroprotection by pentoxyfilline against stress-induced gastric damage. Role of lipid peroxidation, antioxidizing enzymes and proinflammatory cytokines. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2004 Jun:55(2):337-55
[PubMed PMID: 15213357]
[13]
Lin HI, Chu SJ, Wang D, Feng NH. Pharmacological modulation of TNF production in macrophages. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2004 Feb:37(1):8-15
[PubMed PMID: 15060681]
[14]
Vardareli E, Saricam T, Koken T, Degirmenci I, Aral E, Erenoglu E. The effect of alpha-tocopherol and pentoxyfilline on ischemia-reperfusion induced liver injury in rats. Hepato-gastroenterology. 1998 Sep-Oct:45(23):1505-8
[PubMed PMID: 9840094]
[15]
Golbasi I, Akbas H, Ozdem S, Ukan S, Ozdem SS, Kabukçu H, Turkay C, Bayezid O. The effect of pentoxifylline on haemolysis during cardiopulmonary bypass in open-heart surgery. Acta cardiologica. 2006 Feb:61(1):7-11
[PubMed PMID: 16485727]
[16]
Mansourian S, Bina P, Fehri A, Karimi AA, Boroumand MA, Abbasi K. Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). Anatolian journal of cardiology. 2015:15(12):1014-9. doi: 10.5152/akd.2014.5883. Epub 2014 Dec 31
[PubMed PMID: 25880052]
Level 3 (low-level) evidence
[17]
Han SJ, Kim HJ, Kim DJ, Sheen SS, Chung CH, Ahn CW, Kim SH, Cho YW, Park SW, Kim SK, Kim CS, Kim KW, Lee KW. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetology & metabolic syndrome. 2015:7():64. doi: 10.1186/s13098-015-0060-1. Epub 2015 Jul 19
[PubMed PMID: 26300986]
Level 2 (mid-level) evidence
[18]
Vaizova OE, Vengerovsky AI, Alifirova VM. [Endothelium-protective effects of vinpocetine, pentoxifylline and enalapril in patients with chronic brain ischemia]. Eksperimental'naia i klinicheskaia farmakologiia. 2011:74(4):10-3
[PubMed PMID: 21678652]
[20]
Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 1984 Jul:35(7):407-17
[PubMed PMID: 6380349]
[21]
De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World journal of gastroenterology. 2009 Apr 7:15(13):1613-9
[PubMed PMID: 19340904]
Level 1 (high-level) evidence
[22]
Stana J, Stergar J, Gradišnik L, Flis V, Kargl R, Fröhlich E, Stana Kleinschek K, Mohan T, Maver U. Multilayered Polysaccharide Nanofilms for Controlled Delivery of Pentoxifylline and Possible Treatment of Chronic Venous Ulceration. Biomacromolecules. 2017 Sep 11:18(9):2732-2746. doi: 10.1021/acs.biomac.7b00523. Epub 2017 Aug 22
[PubMed PMID: 28776978]
[23]
Hosseini F, Mohammadbeigi A, Aghaali M, Borujerdi R, Parham M. Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2019:24():89. doi: 10.4103/jrms.JRMS_115_18. Epub 2019 Oct 25
[PubMed PMID: 31741661]
Level 1 (high-level) evidence
[24]
Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. European journal of pediatrics. 1994 Sep:153(9):663-7
[PubMed PMID: 7957426]
[25]
Best BM, Burns JC, DeVincenzo J, Phelps SJ, Blumer JL, Wilson JT, Capparelli EV, Connor JD, Pediatric Pharmacology Research Unit Network. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. Current therapeutic research, clinical and experimental. 2003 Feb:64(2):96-115. doi: 10.1016/S0011-393X(03)00018-3. Epub
[PubMed PMID: 24944359]
[26]
Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Annals of internal medicine. 1996 May 15:124(10):891-3
[PubMed PMID: 8610918]
[27]
Sacerdote A. Treatment of homozygous sickle cell disease with pentoxifylline. Journal of the National Medical Association. 1999 Aug:91(8):466-70
[PubMed PMID: 12656436]
[28]
Beermann B, Ings R, Månsby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clinical pharmacology and therapeutics. 1985 Jan:37(1):25-8
[PubMed PMID: 3965236]
[29]
Poondru S, Devaraj R, Boinpally RR, Yamsani MR. Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. Pharmacological research. 2001 Mar:43(3):301-5
[PubMed PMID: 11401423]
[30]
Garcia FA, Pinto SF, Cavalcante AF, Lucetti LT, Menezes SM, Felipe CF, Alves AP, Brito GA, Cerqueira GS, Viana GS. Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas. SpringerPlus. 2014:3():283. doi: 10.1186/2193-1801-3-283. Epub 2014 Jun 5
[PubMed PMID: 24991532]
[31]
Silver MR, Kroboth PD. Pentoxifylline in end-stage renal disease. Drug intelligence & clinical pharmacy. 1987 Dec:21(12):976-8
[PubMed PMID: 3428162]